Ireland's Trinity Biotech Q1 revenue rises on HIV test sales
Trinity Biotech Plc Sponsored ADR Class A TRIB | 0.00 |
Overview
Ireland diagnostics firm's Q1 2026 revenue rose 43% yr/yr, driven by rapid HIV and haemoglobin test sales
Gross margin for Q1 improved to 35.4% from 25.2%, supported by transformation plan changes
Company received purchase orders for over 2 mln rapid HIV tests, reinforcing strong demand outlook
Outlook
Company expects new HIV test orders to support 2026 revenue and profitability targets
Trinity Biotech sees renewed, broad-based demand for rapid HIV diagnostics in global markets
Company expects commercial scale-up of outsourced UniGold HIV production to be in place Q3 2026
Result Drivers
RAPID HIV SALES - Higher TrinScreen HIV sales and new orders contributed to revenue growth
OPERATING STRUCTURE CHANGES - Gross margin improvement supported by changes under Comprehensive Transformation Plan
OUTSOURCED MANUFACTURING - Scale-up of outsourced UniGold HIV production expected to further improve margins and cashflow
Company press release: ID:nGNX2sR3yT
Key Details
Metric |
Beat/Miss |
Actual |
Consensus Estimate |
Q1 Revenue |
|
$10.80 mln |
|
Q1 Gross Margin |
|
35.40% |
|
Q1 Gross Profit |
|
$3.80 mln |
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.